Horowitz M S, Pehta J C
V.I. Technologies, New York, USA.
Vox Sang. 1998;74 Suppl 1:231-5. doi: 10.1111/j.1423-0410.1998.tb05478.x.
Clinical studies of SD-Plasma (SDP) have included treatment of patients with both the acute and chronic relapsing (CRTTP) forms of TTP and replacement of coagulation factors in patients with congenital deficiencies. With the infusion of SDP in 6 patients with CRTTP, platelet counts rose, LDH values dropped, hemoglobin levels remained constant, and the patients continued in good health. In an FFP-controlled study in acute TTP, 16 patients were exchanged with SDP and 10 with FFP. There was no difference between the two groups in patient survival; relapse or remission rate; incidence of treatment resistance; or in per patient total volume infused, number of treatments, average volume per treatment, or number of relapses. Finally, 48 coagulation factor-deficient patients received SDP for surgical prophylaxis, active bleeding and routine prophylaxis for Factor XIII deficiency. The expected levels of the deficient factors were achieved, and the treating physicians concluded that there was control of bleeding.
SD血浆（SDP）的临床研究包括对急性和慢性复发性血栓性血小板减少性紫癜（CRTTP）患者的治疗，以及对先天性凝血因子缺乏患者的凝血因子替代治疗。对6例CRTTP患者输注SDP后，血小板计数上升，乳酸脱氢酶值下降，血红蛋白水平保持稳定，患者持续保持健康状态。在一项急性血栓性血小板减少性紫癜的新鲜冰冻血浆对照研究中，16例患者接受了SDP置换治疗，10例患者接受了新鲜冰冻血浆置换治疗。两组在患者生存率、复发或缓解率、治疗抵抗发生率方面，以及每位患者的总输注量、治疗次数、每次治疗的平均量或复发次数方面均无差异。最后，48例凝血因子缺乏患者接受了SDP用于手术预防、活动性出血以及对XIII因子缺乏的常规预防。达到了缺乏因子的预期水平，治疗医生得出出血得到控制的结论。
